Unlocking cancer vaccine potential: What are the key factors?

References

• Chen S, Cao Z, Prettner K, Kuhn M, Yang J, Jiao L, Wang Z, Li W, Geldsetzer P, Bärnighausen T, et al. Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol. 2023;9(4):465–13. doi:10.1001/jamaoncol.2022.7826.
   PubMed Web of Science ®Google Scholar
• Ward ZJ, Scott AM, Hricak H, Atun R. Global costs, health benefits, and economic benefits of scaling up treatment and imaging modalities for survival of 11 cancers: a simulation-based analysis. Lancet Oncol. 2021;22(3):341–50. doi:10.1016/S1470-2045(20)30750-6.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Whitaker K. Earlier diagnosis: the importance of cancer symptoms. Lancet Oncol. 2020;21(1):6–8. doi:10.1016/S1470-2045(19)30658-8.
   PubMed Web of Science ®Google Scholar
• Price S, Spencer A, Zhang X, Ball S, Lyratzopoulos G, Mujica-Mota R, Stapley S, Ukoumunne OC, Hamilton W. Trends in time to cancer diagnosis around the period of changing national guidance on referral of symptomatic patients: a serial cross-sectional study using UK electronic healthcare records from 2006–17. Cancer Epidemiol. 2020;69:101805. doi:10.1016/j.canep.2020.101805.
   PubMed Web of Science ®Google Scholar
• Swanton C, Neal RD, Johnson PWM, Dur CC, Hamilton SA, Zhang N, Kumar H, Sasieni P. NHS-Galleri trial design: equitable study recruitment tactics for targeted population-level screening with a multi-cancer early detection (MCED) test. J Clin Orthod. 2022;40:6606–6606. doi:10.1200/JCO.2022.40.16_suppl.TPS6606.
   Google Scholar
• Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707–23. doi:10.1016/j.cell.2017.01.017.
   PubMed Web of Science ®Google Scholar
• Tran G, Zafar SY. Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med. 2018;6(9):166. doi:10.21037/atm.2018.03.28.
   PubMed Web of Science ®Google Scholar
• Ventola CL. Cancer immunotherapy, Part 3: challenges and future trends. P T. 2017;42:514–21.
   PubMedGoogle Scholar
• Green AK. Challenges in assessing the cost-effectiveness of cancer immunotherapy. JAMA Netw Open. 2021;4:e2034020. doi:10.1001/jamanetworkopen.2020.34020.
   PubMed Web of Science ®Google Scholar
• Khattak A, Weber JS, Meniawy T, Taylor MH, Ansstas G, Kim KB, McKean M, Long GV, Sullivan RJ, Faries MB, et al. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. J Clin Oncol. 2023;41:9503–9503. suppl 17; abstr LBA9503. doi:10.1200/JCO.2023.41.17_suppl.LBA9503.
   Google Scholar
• Esfahani K, Roudaia L, Buhlaiga N, Del Rincon SV, Papneja N, WH M Jr. A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol. 2020;27:S87–97. doi:10.3747/co.27.5223.
   PubMed Web of Science ®Google Scholar
• Tagliamonte M, Cavalluzzo B, Mauriello A, Ragone C, Buonaguro FM, Tornesello ML, Buonaguro L. Molecular mimicry and cancer vaccine development. Mol Cancer. 2023;22:75. doi:10.1186/s12943-023-01776-0.
   PubMed Web of Science ®Google Scholar
• Lang F, Schrörs B, Löwer M, Türeci Ö, Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discov. 2022;21:261–82. doi:10.1038/s41573-021-00387-y.
   PubMed Web of Science ®Google Scholar
• Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–6. doi:10.1038/nature23003.
   PubMed Web of Science ®Google Scholar
• Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14:135–46. doi:10.1038/nrc3670.
   PubMed Web of Science ®Google Scholar
• Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21(5):298–312. doi:10.1038/s41568-021-00339-z.
   PubMed Web of Science ®Google Scholar
• Bedran G, Gasser H-C, Weke K, Wang T, Bedran D, Laird A, Battail C, Zanzotto FM, Pesquita C, Axelson H, et al. The immunopeptidome from a genomic perspective: establishing the noncanonical landscape of MHC class I–associated peptides. Cancer Immunol Res. 2023;11:747–62. doi:10.1158/2326-6066.CIR-22-0621.
   PubMed Web of Science ®Google Scholar
• Sellars MC, Wu CJ, Fritsch EF. Cancer vaccines: building a bridge over troubled waters. Cell. 2022;185(15):2770–88. doi:10.1016/j.cell.2022.06.035.
   PubMed Web of Science ®Google Scholar
• Jin K-T, Du W-L, Liu Y-Y, Lan H-R, Si J-X, Mou X-Z. Oncolytic virotherapy in solid tumors: the challenges and achievements. Cancers. 2021;13:588. doi:10.3390/cancers13040588.
   PubMed Web of Science ®Google Scholar
• Ladak RJ, He AJ, Huang Y-H, Ding Y. The Current landscape of mRNA vaccines against viruses and cancer-A mini review. Front Immunol. 2022;13:885371. doi:10.3389/fimmu.2022.885371.
   PubMed Web of Science ®Google Scholar
• Elsheikh R, Makram AM, Huy NT. Therapeutic cancer vaccines and their future implications. Vaccines (Basel). 2023;11:11. doi:10.3390/vaccines11030660.
   Web of Science ®Google Scholar
• Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang X-Y. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 2013;119:421–75.
   PubMed Web of Science ®Google Scholar
• Dobosz P, Dzieciątkowski T. The intriguing history of cancer immunotherapy. Front Immunol. 2019;10:2965. doi:10.3389/fimmu.2019.02965.
   PubMed Web of Science ®Google Scholar
• Rastogi I, Muralidhar A, McNeel DG. Vaccines as treatments for prostate cancer. Nat Rev Urol. 2023;20(9):544–59. doi:10.1038/s41585-023-00739-w.
   PubMed Web of Science ®Google Scholar
• Sutherland SIM, Ju X, Horvath LG, Clark GJ. Moving on from sipuleucel-T: new dendritic cell vaccine strategies for prostate cancer. Front Immunol. 2021;12:641307. doi:10.3389/fimmu.2021.641307.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Sharma AR, Bhattacharya M, Lee S-S. From COVID-19 to cancer mRNA vaccines: moving from bench to clinic in the vaccine landscape. Front Immunol. 2021;12:679344. doi:10.3389/fimmu.2021.679344.
   PubMedGoogle Scholar
• Wherry EJ, Barouch DH. T cell immunity to COVID-19 vaccines. Science. 2022;377(6608):821–2. doi:10.1126/science.add2897.
   PubMed Web of Science ®Google Scholar
• Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Kent SJ, Triccas JA, Khoury DS, Davenport MP, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2022;3(1):e52–61. doi:10.1016/S2666-5247(21)00267-6.
   PubMedGoogle Scholar
• Gumber D, Wang LD. Improving CAR-T immunotherapy: overcoming the challenges of T cell exhaustion. EBioMedicine. 2022;77:103941. doi:10.1016/j.ebiom.2022.103941.
   PubMed Web of Science ®Google Scholar
• Nüssing S, Trapani JA, Parish IA. Revisiting T cell tolerance as a checkpoint target for cancer immunotherapy. Front Immunol. 2020;11:589641. doi:10.3389/fimmu.2020.589641.
   PubMed Web of Science ®Google Scholar
• Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21:360–78. doi:10.1038/s41568-021-00346-0.
   PubMed Web of Science ®Google Scholar
• Vishweshwaraiah YL, Dokholyan NV. mRNA vaccines for cancer immunotherapy. Front Immunol. 2022;13:1029069. doi:10.3389/fimmu.2022.1029069.
   PubMed Web of Science ®Google Scholar
• Escamilla-Tilch M, Filio-Rodríguez G, García-Rocha R, Mancilla-Herrera I, Mitchison NA, Ruiz-Pacheco JA, Sánchez‐García FJ, Sandoval‐Borrego D, Vázquez‐Sánchez EA. The interplay between pathogen-associated and danger-associated molecular patterns: an inflammatory code in cancer? Immunol Cell Biol. 2013;91:601–10. doi:10.1038/icb.2013.58.
   PubMed Web of Science ®Google Scholar
• Li D, Wu M. Pattern recognition receptors in health and diseases. Signal Transduct Target Ther. 2021;6(1):291. doi:10.1038/s41392-021-00687-0.
   PubMed Web of Science ®Google Scholar
• Willsmore ZN, Harris RJ, Crescioli S, Hussein K, Kakkassery H, Thapa D, Cheung A, Chauhan J, Bax HJ, Chenoweth A, et al. B cells in patients with melanoma: implications for treatment with checkpoint inhibitor antibodies. Front Immunol. 2020;11:622442. doi:10.3389/fimmu.2020.622442.
   PubMed Web of Science ®Google Scholar
• Litchfield K, Reading JL, Puttick C, Thakkar K, Abbosh C, Bentham R, Watkins TBK, Rosenthal R, Biswas D, Rowan A, et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell. 2021;184(3):596–614.e14. doi:10.1016/j.cell.2021.01.002.
   PubMed Web of Science ®Google Scholar
• McCarthy PM, Valdera FA, Smolinsky TR, Adams AM, O’Shea AE, Thomas KK, Van Decar S, Carpenter EL, Tiwari A, Myers JW, et al. Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials. Front Immunol. 2023;14:1090533. doi:10.3389/fimmu.2023.1090533.
   PubMed Web of Science ®Google Scholar
• Yan Y, Cao S, Liu X, Harrington SM, Bindeman WE, Adjei AA, Jang JS, Jen J, Li Y, Chanana P, et al. CX3CR1 identifies PD-1 therapy–responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight. 2018;3:3. doi:10.1172/jci.insight.97828.
   Web of Science ®Google Scholar
• Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, Gao P, Bandyopadhyay S, Sun H, Zhao Z, et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature. 2022;602(7897):503–9. doi:10.1038/s41586-021-04390-6.
   PubMed Web of Science ®Google Scholar
• D’Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, Grupp S, Tap WD, Chagin K, Binder GK, et al. Antitumor activity associated with prolonged persistence of adoptively transferred NY-ESO-1 c259T cells in synovial sarcoma. Cancer Discov. 2018;8(8):944–57. doi:10.1158/2159-8290.CD-17-1417.
   PubMed Web of Science ®Google Scholar
• Crompton JG, Sukumar M, Restifo NP. Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. Immunol Rev. 2014;257(1):264–76. doi:10.1111/imr.12135.
   PubMed Web of Science ®Google Scholar
• Duan L-J, Wang Q, Zhang C, Yang D-X, Zhang X-Y. Potentialities and challenges of mRNA vaccine in cancer immunotherapy. Front Immunol. 2022;13:923647. doi:10.3389/fimmu.2022.923647.
   PubMed Web of Science ®Google Scholar
• Chang R, Gulley JL, Fong L. Vaccinating against cancer: getting to prime time. J Immunother Cancer. 2023;11:11. doi:10.1136/jitc-2022-006628.
   Web of Science ®Google Scholar
• Cuzzubbo S, Mangsbo S, Nagarajan D, Habra K, Pockley AG, McArdle SEB. Cancer vaccines: adjuvant potency, importance of age, lifestyle, and treatments. Front Immunol. 2020;11:615240. doi:10.3389/fimmu.2020.615240.
   PubMed Web of Science ®Google Scholar
• Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15(1):28. doi:10.1186/s13045-022-01247-x.
   PubMed Web of Science ®Google Scholar
• Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21(6):345–59. doi:10.1038/s41568-021-00347-z.
   PubMed Web of Science ®Google Scholar
• Kim SK, Cho SW. The evasion mechanisms of cancer immunity and drug intervention in the tumor microenvironment. Front Pharmacol. 2022;13:868695. doi:10.3389/fphar.2022.868695.
   PubMed Web of Science ®Google Scholar
• Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y, Wang T, Yan F, Yang S, Xia X, et al. Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther. 2023;8(1):149. doi:10.1038/s41392-023-01408-5.
   PubMed Web of Science ®Google Scholar
• Nia HT, Munn LL, Jain RK. Physical traits of cancer. Science. 2020;370:370. doi:10.1126/science.aaz0868.
   Web of Science ®Google Scholar
• Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31–46. doi:10.1158/2159-8290.CD-21-1059.
   PubMed Web of Science ®Google Scholar
• Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618(7963):144–50. doi:10.1038/s41586-023-06063-y.
   PubMed Web of Science ®Google Scholar
• Pharma H. Hookipa pharma reports first Quarter 2023 financial results and recent business highlights. Hookipa Pharma Inc n.d. [accessed 2024 Mar 2]. https://ir.hookipapharma.com/node/8826/pdf.
   Google Scholar
• Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA, Kedl RM. T cell responses: naive to memory and everything in between. Adv Physiol Educ. 2013;37:273–83. doi:10.1152/advan.00066.2013.
   PubMed Web of Science ®Google Scholar
• Dolgin E. Personalized cancer vaccines pass first major clinical test. Nat Rev Drug Discov. 2023;22(8):607–9. doi:10.1038/d41573-023-00118-5.
   PubMed Web of Science ®Google Scholar
• Kallingal A, Olszewski M, Maciejewska N, Brankiewicz W, Baginski M. Cancer immune escape: the role of antigen presentation machinery. J Cancer Res Clin Oncol. 2023;149(10):8131–41. doi:10.1007/s00432-023-04737-8.
   PubMed Web of Science ®Google Scholar
• Chang S, Kohrt H, Maecker HT. Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother. 2014;63(7):713–9. doi:10.1007/s00262-014-1521-3.
   PubMed Web of Science ®Google Scholar
• Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20(1):41. doi:10.1186/s12943-021-01335-5.
   PubMed Web of Science ®Google Scholar
• Batista-Duharte A, Hassouneh F, Alvarez-Heredia P, Pera A, Solana R. Immune checkpoint inhibitors for vaccine improvements: Current status and new approaches. Pharmaceutics. 2022;14:14. doi:10.3390/pharmaceutics14081721.
   Web of Science ®Google Scholar
• Wang L, Geng H, Liu Y, Liu L, Chen Y, Wu F, Liu Z, Ling S, Wang Y, Zhou L. Hot and cold tumors: immunological features and the therapeutic strategies. MedComm. 2023;4:e343. doi:10.1002/mco2.343.
   PubMedGoogle Scholar
• Paston SJ, Brentville VA, Symonds P, Durrant LG. Cancer vaccines, adjuvants, and delivery systems. Front Immunol. 2021;12:627932. doi:10.3389/fimmu.2021.627932.
   PubMed Web of Science ®Google Scholar
• Smithy JW, Blouin A, Diamond LC, Postow M. Ensuring equity in the era of HLA-restricted cancer therapeutics. J Immunother Cancer. 2022;10:10. doi:10.1136/jitc-2022-005600.
   Web of Science ®Google Scholar
• Farlow A, Torreele E, Gray G, Ruxrungtham K, Rees H, Prasad S, Gomez C, Sall A, Magalhães J, Olliaro P, et al. The future of epidemic and pandemic vaccines to serve global public health needs. Vaccines (Basel). 2023;11:11. doi:10.3390/vaccines11030690.
   Google Scholar
• Dyer O. Covid-19: countries are learning what others paid for vaccines. BMJ. 2021;372:n281. doi:10.1136/bmj.n281.
   PubMed Web of Science ®Google Scholar
• Lin MJ, Svensson-Arvelund J, Lubitz GS, Marabelle A, Melero I, Brown BD, Brody JD. Cancer vaccines: the next immunotherapy frontier. Nat Cancer. 2022;3:911–26. doi:10.1038/s43018-022-00418-6.
   PubMedGoogle Scholar
• Khan ST, Montroy J, Forbes N, Bastin D, Kennedy MA, Diallo J-S, Kekre N, Fergusson DA, Lalu M, Auer RC, et al. Safety and efficacy of autologous tumour cell vaccines as a cancer therapeutic to treat solid tumours and haematological malignancies: a meta-analysis protocol for two systematic reviews. BMJ Open. 2020;10(6):e034714. doi:10.1136/bmjopen-2019-034714.
   PubMed Web of Science ®Google Scholar
• Tang F, Tie Y, Tu C, Wei X. Surgical trauma-induced immunosuppression in cancer: recent advances and the potential therapies. Clin Transl Med. 2020;10(1):199–223. doi:10.1002/ctm2.24.
   PubMed Web of Science ®Google Scholar
• Sahin U, Oehm P, Derhovanessian E, Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D, Kuhn AN, Omokoko T, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107–12. doi:10.1038/s41586-020-2537-9.
   PubMed Web of Science ®Google Scholar
• Badrinath S, Dellacherie MO, Li A, Zheng S, Zhang X, Sobral M, Pyrdol JW, Smith KL, Lu Y, Haag S, et al. A vaccine targeting resistant tumours by dual T cell plus NK cell attack. Nature. 2022;606(7916):992–8. doi:10.1038/s41586-022-04772-4.
   PubMed Web of Science ®Google Scholar
• Kalaora S, Lee JS, Barnea E, Levy R, Greenberg P, Alon M, Yagel G, Bar Eli G, Oren R, Peri A, et al. Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma. Nat Commun. 2020;11(1):896. doi:10.1038/s41467-020-14639-9.
   PubMed Web of Science ®Google Scholar
• Spiliopoulou P, Janse van Rensburg HJ, Avery L, Kulasingam V, Razak A, Bedard P, Hansen A, Chruscinski A, Wang B, Kulikova M, et al. Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. Cell Death Disease. 2023;14(1):49. doi:10.1038/s41419-022-05548-4.
   PubMed Web of Science ®Google Scholar
• Peri A, Salomon N, Wolf Y, Kreiter S, Diken M, Samuels Y. The landscape of T cell antigens for cancer immunotherapy. Nat Cancer. 2023;4(7):937–54. doi:10.1038/s43018-023-00588-x.
   PubMedGoogle Scholar
• Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Sig Transduct Target Ther. 2023;8:9. doi:10.1038/s41392-022-01270-x.
   PubMed Web of Science ®Google Scholar
• Zhang B, Bassani-Sternberg M. Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery. J Immunother Cancer. 2023;11:11. doi:10.1136/jitc-2023-007073.
   Web of Science ®Google Scholar
• Becker JP, Riemer AB. The importance of being presented: target validation by immunopeptidomics for epitope-specific immunotherapies. Front Immunol. 2022;13:883989. doi:10.3389/fimmu.2022.883989.
   PubMed Web of Science ®Google Scholar
• Kula T, Dezfulian MH, Wang CI, Abdelfattah NS, Hartman ZC, Wucherpfennig KW, Lyerly HK, Elledge SJ. T-Scan: a genome-wide method for the systematic discovery of T cell epitopes. Cell. 2019;178:1016–28.e13. doi:10.1016/j.cell.2019.07.009.
   PubMed Web of Science ®Google Scholar
• Morse MA, Gwin WR III, Mitchell DA. Vaccine therapies for cancer: then and Now. Target Oncol. 2021;16:121–52. doi:10.1007/s11523-020-00788-w.
   PubMed Web of Science ®Google Scholar
• Cruz-Tapias P, Castiblanco J, Anaya J-M. Major histocompatibility complex: antigen processing and presentation. El Rosario University Press; 2013.
   Google Scholar
• Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56(10):2188–205. doi:10.1016/j.immuni.2023.09.011.
   PubMed Web of Science ®Google Scholar
• Reza HM, Sultana F, Bari R, Cole J, Baqui AH. Local distribution infrastructure and robust vaccine manufacturing facilities in LMICs should be prioritised to tackle ongoing and future pandemic risk. Lancet Reg Health Southeast Asia. 2023;11:100158. doi:10.1016/j.lansea.2023.100158.
   PubMedGoogle Scholar
• Parry H, Bruton R, Tut G, Ali M, Stephens C, Greenwood D, Faustini S, Hughes S, Huissoon A, Meade R, et al. Immunogenicity of single vaccination with BNT162b2 or ChAdOx1 nCoV-19 at 5–6 weeks post vaccine in participants aged 80 years or older: an exploratory analysis. Lancet Healthy Longev. 2021;2:e554–60. doi:10.1016/S2666-7568(21)00169-0.
   PubMedGoogle Scholar
• Ward H, Whitaker M, Flower B, Tang SN, Atchison C, Darzi A, Donnelly CA, Cann A, Diggle PJ, Ashby D, et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat Commun. 2022;13(1):907. doi:10.1038/s41467-022-28527-x.
   PubMed Web of Science ®Google Scholar
• Palgen J-L, Feraoun Y, Dzangué-Tchoupou G, Joly C, Martinon F, Le Grand R. Optimize prime/boost vaccine strategies: trained immunity as a new player in the game. Front Immunol. 2021;12:612747. doi:10.3389/fimmu.2021.612747.
   PubMed Web of Science ®Google Scholar
• Wang B, Pei J, Xu S, Liu J, Yu J. Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities. Front Immunol. 2023;14:1246682. doi:10.3389/fimmu.2023.1246682.
   PubMed Web of Science ®Google Scholar
• Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–21. doi:10.1038/nature22991.
   PubMed Web of Science ®Google Scholar
• Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234–9. doi:10.1038/s41586-018-0792-9.
   PubMed Web of Science ®Google Scholar
• Tang M, Cai J-H, Diao H-Y, Guo W-M, Yang X, Xing S. The progress of peptide vaccine clinical trials in gynecologic oncology. Hum Vaccin Immunother. 2022;18:2062982. doi:10.1080/21645515.2022.2062982.
   PubMed Web of Science ®Google Scholar
• Liu W, Tang H, Li L, Wang X, Yu Z, Li J. Peptide-based therapeutic cancer vaccine: Current trends in clinical application. Cell Prolif. 2021;54(5):e13025. doi:10.1111/cpr.13025.
   PubMed Web of Science ®Google Scholar
• Mizukoshi E, Nakagawa H, Tamai T, Kitahara M, Fushimi K, Nio K, Terashima T, Iida N, Arai K, Yamashita T, et al. Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells. Nat Commun. 2022;13(1):3123. doi:10.1038/s41467-022-30861-z.
   PubMed Web of Science ®Google Scholar
• Nelde A, Rammensee H-G, Walz JS. The peptide vaccine of the future. Molecular & Cellular Proteomics: MCP. 2021;20:100022. doi:10.1074/mcp.R120.002309.
   PubMed Web of Science ®Google Scholar
• Mohsen MO, Bachmann MF. Virus-like particle vaccinology, from bench to bedside. Cell Mol Immunol. 2022;19(9):993–1011. doi:10.1038/s41423-022-00897-8.
   PubMed Web of Science ®Google Scholar
• McFall-Boegeman H, Huang X. Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines. Expert Rev Vaccines. 2022;21(4):453–69. doi:10.1080/14760584.2022.2029415.
   PubMed Web of Science ®Google Scholar
• Ruzzi F, Semprini MS, Scalambra L, Palladini A, Angelicola S, Cappello C, Pittino OM, Nanni P, Lollini P-L. Virus-like particle (VLP) vaccines for cancer immunotherapy. Int J Mol Sci. 2023;24:12963. doi:10.3390/ijms241612963.
   PubMed Web of Science ®Google Scholar
• Bijker MS, van den Eeden SJF, Franken KL, Melief CJM, van der Burg SH, Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol. 2008;38:1033–42. doi:10.1002/eji.200737995.
   PubMed Web of Science ®Google Scholar
• Dailey GP, Crosby EJ, Hartman ZC. Cancer vaccine strategies using self-replicating RNA viral platforms. Cancer Gene Ther. 2023;30(6):794–802. doi:10.1038/s41417-022-00499-6.
   PubMed Web of Science ®Google Scholar
• Melief CJM, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125(9):3401–12. doi:10.1172/JCI80009.
   PubMed Web of Science ®Google Scholar
• Riccardo F, Bolli E, Macagno M, Arigoni M, Cavallo F, Quaglino E. Chimeric DNA vaccines: an effective way to overcome immune tolerance. Curr Top Microbiol Immunol. 2017;405:99–122.
   PubMed Web of Science ®Google Scholar
• Pandya A, Shah Y, Kothari N, Postwala H, Shah A, Parekh P, Chorawala MR. The future of cancer immunotherapy: DNA vaccines leading the way. Med Oncol. 2023;40:200. doi:10.1007/s12032-023-02060-3.
   PubMed Web of Science ®Google Scholar
• Bernard M-C, Bazin E, Petiot N, Lemdani K, Commandeur S, Verdelet C, Margot S, Perkov V, Ripoll M, Garinot M, et al. The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system. Mol Ther Nucleic Acids. 2023;32:794–806. doi:10.1016/j.omtn.2023.05.004.
   PubMedGoogle Scholar
• Alameh M-G, Tombácz I, Bettini E, Lederer K, Sittplangkoon C, Wilmore JR, Wilmore JR, Gaudette BT, Soliman OY, Pine M, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54:2877–92.e7. doi:10.1016/j.immuni.2021.11.001.
   PubMed Web of Science ®Google Scholar
• Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, Kent SJ, Triccas JA, Davenport MP, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–11. doi:10.1038/s41591-021-01377-8.
   PubMed Web of Science ®Google Scholar
• Nitika, Wei J, Hui A-M. The delivery of mRNA vaccines for therapeutics. Life. 2022;12. doi:10.3390/life12081254.
   PubMedGoogle Scholar
• Aguinam ET, Nadesalingam A, Chan A, Smith P, Paloniemi M, Cantoni D, Gronlund J, Gronlund H, Carnell GW, Castillo-Olivares J, et al. Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies. J Allergy Clin Immunol Glob. 2023;2:100091. doi:10.1016/j.jacig.2023.100091.
   PubMedGoogle Scholar
• Weide B, Carralot J-P, Reese A, Scheel B, Eigentler TK, Hoerr I, Rammensee H-G, Garbe C, Pascolo S. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother (1991). 2008;31:180–8. doi:10.1097/CJI.0b013e31815ce501.
   PubMed Web of Science ®Google Scholar
• Lorentzen CL, Haanen JB, Met Ö, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022;23:e450–8. doi:10.1016/S1470-2045(22)00372-2.
   PubMed Web of Science ®Google Scholar
• Kim H, Liew D, Goodall S. Cost-effectiveness and financial risks associated with immune checkpoint inhibitor therapy. Br J Clin Pharmacol. 2020;86(9):1703–10. doi:10.1111/bcp.14337.
   PubMed Web of Science ®Google Scholar
• McCann N, O’Connor D, Lambe T, Pollard AJ. Viral vector vaccines. Curr Opin Immunol. 2022;77:102210. doi:10.1016/j.coi.2022.102210.
   PubMed Web of Science ®Google Scholar
• Larocca C, Schlom J. Viral vector-based therapeutic cancer vaccines. Cancer J. 2011;17(5):359–71. doi:10.1097/PPO.0b013e3182325e63.
   PubMed Web of Science ®Google Scholar
• Travieso T, Li J, Mahesh S, Mello JDFRE, Blasi M. The use of viral vectors in vaccine development. NPJ Vaccines. 2022;7:75. doi:10.1038/s41541-022-00503-y.
   PubMed Web of Science ®Google Scholar
• Ahmadi SE, Soleymani M, Shahriyary F, Amirzargar MR, Ofoghi M, Fattahi MD, Safa M. Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy. Cancer Gene Ther. 2023;30:936–54. doi:10.1038/s41417-023-00597-z.
   PubMed Web of Science ®Google Scholar
• Yarnoff B, Bodhaine S, Cohen E, Buck PO. Time and cost of administering COVID-19 mRNA vaccines in the United States. Hum Vaccin Immunother. 2021;17:3871–5. doi:10.1080/21645515.2021.1974289.
   PubMed Web of Science ®Google Scholar
• Ruiz FJ, Torres-Rueda S, Pearson CAB, Bergren E, Okeke C, Procter SR, Madriz-Montero A, Jit M, Vassall A, Uzochukwu BSC, et al. What, how and who: cost-effectiveness analyses of COVID-19 vaccination to inform key policies in Nigeria. PloS Glob Public Health. 2023;3(3):e0001693. doi:10.1371/journal.pgph.0001693.
   PubMedGoogle Scholar
• Light DW, Lexchin J. The costs of coronavirus vaccines and their pricing. J R Soc Med. 2021;114(11):502–4. doi:10.1177/01410768211053006.
   PubMed Web of Science ®Google Scholar
• Cancer. Barinthus biotherapeutics 2023. [accessed 2024 Jan 3]. https://www.barinthusbio.com/pipeline/cancer/.
   Google Scholar
• Fakih M, Le DT, Pedersen KS, Shields AF, Shah MA, Mukherjee S, Delaite P, Faivre T, D’Alise AM, Leoni G, et al. First clinical and immunogenicity results including all subjects enrolled in a phase I study of nous-209, an off-the-shelf immunotherapy, with pembrolizumab, for the treatment of tumors with a deficiency in mismatch repair/microsatellite instability (dMMR/MSI). J Clin Oncol. 2022;40:2515. doi:10.1200/JCO.22.00506.
   PubMed Web of Science ®Google Scholar
• Palmer CD, Rappaport AR, Davis MJ, Hart MG, Scallan CD, Hong S-J, Gitlin L, Kraemer LD, Kounlavouth S, Yang A, et al. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nat Med. 2022;28(8):1619–29. doi:10.1038/s41591-022-01937-6.
   PubMed Web of Science ®Google Scholar
• Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med. 2007;357(19):1903–15. doi:10.1056/NEJMoa066092.
   PubMed Web of Science ®Google Scholar
• Bolinger B, Sims S, O’Hara G, de Lara C, Tchilian E, Firner S, Engeler D, Ludewig B, Klenerman P. A new model for CD8+ T cell memory inflation based upon a recombinant adenoviral vector. J Immunol. 2013;190:4162–74. doi:10.4049/jimmunol.1202665.
   PubMed Web of Science ®Google Scholar
• Provine NM, Klenerman P. Adenovirus vector and mRNA vaccines: mechanisms regulating their immunogenicity. Eur J Immunol. 2023;53(6):e2250022. doi:10.1002/eji.202250022.
   PubMed Web of Science ®Google Scholar
• Sutton N, San Francisco Ramos A, Beales E, Smith D, Ikram S, Galiza E, Hsia Y, Heath PT. Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis. Expert Rev Vaccines. 2022;21:1301–18. doi:10.1080/14760584.2022.2098719.
   PubMed Web of Science ®Google Scholar
• Ayati N, Evans S, Zakavi SR, Gruenewald SM. Comparison between viral vector and mRNA based COVID-19 vaccination in prevalence and severity of regional immune reactions, and 18F-FDG PET/CT features. Asia Ocean J Nucl Med Biol. 2023;11:4–12.
   PubMedGoogle Scholar
• Li J-X, Hou L-H, Meng F-Y, Wu S-P, Hu Y-M, Liang Q, Chu K, Zhang Z, Xu J-J, Tang R, et al. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Glob Health. 2017;5:e324–34. doi:10.1016/S2214-109X(16)30367-9.
   PubMed Web of Science ®Google Scholar
• Zhu F, Jin P, Zhu T, Wang W, Ye H, Pan H, Hou L, Li J, Wang X, Wu S, et al. Safety and immunogenicity of a recombinant adenovirus type-5–vectored coronavirus disease 2019 (COVID-19) vaccine with a homologous prime-boost regimen in healthy participants aged ≥6 years: a randomized, double-blind, placebo-controlled, phase 2b trial. Clin Infect Dis. 2022;75:e783–91. doi:10.1093/cid/ciab845.
   PubMed Web of Science ®Google Scholar
• Franke A-C, Hardet R, Prager L, Bentler M, Demeules M, John-Neek P, Jäschke NM, Ha TC, Hacker UT, Adriouch S, et al. Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy. Mol Ther Methods Clin Dev. 2023;29:238–53. doi:10.1016/j.omtm.2023.03.010.
   PubMed Web of Science ®Google Scholar
• Costa Clemens SA, Weckx L, Clemens R, Almeida Mendes AV, Ramos Souza A, Silveira MBV, da Guarda SNF, de Nobrega MM, de Moraes Pinto MI, Gonzalez IGS, et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet. 2022;399(10324):521–9. doi:10.1016/S0140-6736(22)00094-0.
   PubMed Web of Science ®Google Scholar
• Ramirez-Valdez RA, Baharom F, Khalilnezhad A, Fussell SC, Hermans DJ, Schrager AM, Tobin KKS, Lynn GM, Khalilnezhad S, Ginhoux F, et al. Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression. Cell Rep. 2023;42(6):112599. doi:10.1016/j.celrep.2023.112599.
   PubMed Web of Science ®Google Scholar
• Seclì L, Leoni G, Ruzza V, Siani L, Cotugno G, Scarselli E, D’Alise AM. Personalized cancer vaccines go viral: viral vectors in the era of personalized immunotherapy of cancer. IJMS. 2023;24:16591. doi:10.3390/ijms242316591.
   Google Scholar
• Hookipa announces positive phase 1 data and phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO. Hookipa Pharma Inc n.d. [accessed 2024 Jan 3]. https://ir.hookipapharma.com/news-releases/news-release-details/hookipa-announces-positive-phase-1-data-and-phase-2-plans-hb-200.
   Google Scholar
• Morris VK, Kopetz S. Don’t blame the messenger: lessons learned for cancer mRNA vaccines during the COVID-19 pandemic. Nat Rev Cancer. 2022;22(6):317–8. doi:10.1038/s41568-022-00463-4.
   PubMed Web of Science ®Google Scholar
• Yang C-Y, Lin Y-T, Lin L-J, Chang Y-H, Chen H-Y, Wang Y-P, Shih J-Y, Yu C-J, Yang P-C. Stage shift improves lung cancer survival: real-world evidence. J Thorac Oncol. 2023;18:47–56. doi:10.1016/j.jtho.2022.09.005.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708.
   PubMed Web of Science ®Google Scholar
• Furukawa Y, Hamano Y, Shirane S, Kinoshita S, Azusawa Y, Ando J, Nakauchi H, Ando M. Advances in allogeneic cancer cell therapy and future perspectives on “off-the-shelf” T cell therapy using iPSC technology and gene editing. Cells. 2022;11:11. doi:10.3390/cells11020269.
   Web of Science ®Google Scholar
• Topalian SL, Forde PM, Emens LA, Yarchoan M, Smith KN, Pardoll DM. Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy. Cancer Cell. 2023;41(9):1551–66. doi:10.1016/j.ccell.2023.07.011.
   PubMed Web of Science ®Google Scholar
• Pilla L, Ferrone S, Maccalli C. Methods for improving the immunogenicity and efficacy of cancer vaccines. Expert Opin Biol Ther. 2018;18(7):765–84. doi:10.1080/14712598.2018.1485649.
   PubMed Web of Science ®Google Scholar
• Zhao J, Chen Y, Ding Z-Y, Liu J-Y. Safety and efficacy of therapeutic cancer vaccines alone or in combination with immune checkpoint inhibitors in cancer treatment. Front Pharmacol. 2019;10:1184. doi:10.3389/fphar.2019.01184.
   PubMed Web of Science ®Google Scholar
• Marofi F, Motavalli R, Safonov VA, Thangavelu L, Yumashev AV, Alexander M, Shomali N, Chartrand MS, Pathak Y, Jarahian M, et al. CAR T cells in solid tumors: challenges and opportunities. Stem Cell Res Ther. 2021;12(1):81. doi:10.1186/s13287-020-02128-1.
   PubMed Web of Science ®Google Scholar
• Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168. doi:10.3389/fimmu.2019.00168.
   PubMed Web of Science ®Google Scholar
• Yan T, Zhu L, Chen J. Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol. 2023;12(1):14. doi:10.1186/s40164-023-00373-7.
   PubMed Web of Science ®Google Scholar
• Yamey G, Garcia P, Hassan F, Mao W, McDade KK, Pai M, Saha S, Schellekens P, Taylor A, Udayakumar K, et al. It is not too late to achieve global COVID-19 vaccine equity. BMJ. 2022;376:e070650. doi:10.1136/bmj-2022-070650.
   PubMedGoogle Scholar